169 related articles for article (PubMed ID: 24118207)
1. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
[TBL] [Abstract][Full Text] [Related]
2. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
Becker TM; Boyd SC; Mijatov B; Gowrishankar K; Snoyman S; Pupo GM; Scolyer RA; Mann GJ; Kefford RF; Zhang XD; Rizos H
Oncogene; 2014 Feb; 33(9):1158-66. PubMed ID: 23455323
[TBL] [Abstract][Full Text] [Related]
3. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
5. Is Mcl-1L the new anti-apoptotic effector of B-RAFV(600E) in melanoma?
Bergamaschi D
Exp Dermatol; 2014 Feb; 23(2):94. PubMed ID: 24372788
[TBL] [Abstract][Full Text] [Related]
6. High expression of Mcl-1L via the MEK-ERK-phospho-STAT3 (Ser727) pathway protects melanocytes and melanoma from UVB-induced apoptosis.
Fukumoto T; Iwasaki T; Okada T; Hashimoto T; Moon Y; Sakaguchi M; Fukami Y; Nishigori C; Oka M
Genes Cells; 2016 Feb; 21(2):185-99. PubMed ID: 26791143
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
8. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 is required for melanoma cell resistance to anoikis.
Boisvert-Adamo K; Longmate W; Abel EV; Aplin AE
Mol Cancer Res; 2009 Apr; 7(4):549-56. PubMed ID: 19372583
[TBL] [Abstract][Full Text] [Related]
11. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma.
Packer LM; East P; Reis-Filho JS; Marais R
Pigment Cell Melanoma Res; 2009 Dec; 22(6):785-98. PubMed ID: 19682280
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
14. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
15. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression.
Ehsani L; Cohen C; Fisher KE; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):648-51. PubMed ID: 25046227
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.
Corazzari M; Rapino F; Ciccosanti F; Giglio P; Antonioli M; Conti B; Fimia GM; Lovat PE; Piacentini M
Cell Death Differ; 2015 Jun; 22(6):946-58. PubMed ID: 25361077
[TBL] [Abstract][Full Text] [Related]
18. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
19. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
20. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
